| Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug EM Svensson, S Murray, MO Karlsson, KE Dooley Journal of Antimicrobial Chemotherapy 70 (4), 1106-1114, 2015 | 140 | 2015 |
| Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis EM Svensson, F Aweeka, JG Park, F Marzan, KE Dooley, MO Karlsson Antimicrobial agents and chemotherapy 57 (6), 2780-2787, 2013 | 121 | 2013 |
| Clinical pharmacokinetics and pharmacodynamics of rifampicin in human tuberculosis AA Abulfathi, EH Decloedt, EM Svensson, AH Diacon, P Donald, H Reuter Clinical pharmacokinetics 58, 1103-1129, 2019 | 106 | 2019 |
| The potential for treatment shortening with higher rifampicin doses: relating drug exposure to treatment response in patients with pulmonary tuberculosis EM Svensson, RJ Svensson, LHM Te Brake, MJ Boeree, N Heinrich, ... Clinical Infectious Diseases 67 (1), 34-41, 2018 | 99 | 2018 |
| A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria MM Ruth, JJN Sangen, K Remmers, LJ Pennings, E Svensson, ... Journal of Antimicrobial Chemotherapy 74 (4), 935-943, 2019 | 90 | 2019 |
| Population pharmacokinetics of bedaquiline and metabolite M2 in patients with drug‐resistant tuberculosis: the effect of time‐varying weight and albumin EM Svensson, AG Dosne, MO Karlsson CPT: pharmacometrics & systems pharmacology 5 (12), 682-691, 2016 | 84 | 2016 |
| Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection EM Svensson, KE Dooley, MO Karlsson Antimicrobial agents and chemotherapy 58 (11), 6406-6412, 2014 | 84 | 2014 |
| Model-based meta-analysis of rifampicin exposure and mortality in Indonesian tuberculous meningitis trials EM Svensson, S Dian, L Te Brake, AR Ganiem, V Yunivita, ... Clinical Infectious Diseases 71 (8), 1817-1823, 2020 | 75 | 2020 |
| High-dose oral and intravenous rifampicin for the treatment of tuberculous meningitis in predominantly human immunodeficiency virus (HIV)-positive Ugandan adults: a phase II … FV Cresswell, DB Meya, E Kagimu, D Grint, L Te Brake, J Kasibante, ... Clinical Infectious Diseases 73 (5), 876-884, 2021 | 70 | 2021 |
| Population pharmacokinetics and Bayesian dose adjustment to advance TDM of anti-TB drugs MGG Sturkenboom, AG Märtson, EM Svensson, DJ Sloan, KE Dooley, ... Clinical pharmacokinetics 60, 685-710, 2021 | 69 | 2021 |
| Clinical standards for the dosing and management of TB drugs JWC Alffenaar, SL Stocker, LD Forsman, A Garcia-Prats, SK Heysell, ... The International Journal of Tuberculosis and Lung Disease 26 (6), 483-499, 2022 | 65 | 2022 |
| Greater early bactericidal activity at higher rifampicin doses revealed by modeling and clinical trial simulations RJ Svensson, EM Svensson, RE Aarnoutse, AH Diacon, R Dawson, ... The Journal of infectious diseases 218 (6), 991-999, 2018 | 64 | 2018 |
| Modelling of mycobacterial load reveals bedaquiline’s exposure–response relationship in patients with drug-resistant TB EM Svensson, MO Karlsson Journal of Antimicrobial Chemotherapy 72 (12), 3398-3405, 2017 | 59 | 2017 |
| Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis MJE Brill, EM Svensson, M Pandie, G Maartens, MO Karlsson International journal of antimicrobial agents 49 (2), 212-217, 2017 | 58 | 2017 |
| Machine learning and pharmacometrics for prediction of pharmacokinetic data: differences, similarities and challenges illustrated with rifampicin L Keutzer, H You, A Farnoud, J Nyberg, SG Wicha, G Maher-Edwards, ... Pharmaceutics 14 (8), 1530, 2022 | 54 | 2022 |
| Increased bactericidal activity but dose-limiting intolerability at 50 mg· kg− 1 rifampicin LHM Te Brake, V de Jager, K Narunsky, N Vanker, EM Svensson, ... European Respiratory Journal 58 (1), 2021 | 51 | 2021 |
| Clofazimine pharmacokinetics in patients with TB: dosing implications MT Abdelwahab, S Wasserman, JCM Brust, NR Gandhi, G Meintjes, ... Journal of Antimicrobial Chemotherapy 75 (11), 3269-3277, 2020 | 50 | 2020 |
| Current status of pharmacokinetic and safety studies of multidrug-resistant tuberculosis treatment in children AJ Garcia-Prats, EM Svensson, ED Weld, HS Schaaf, AC Hesseling The international journal of tuberculosis and lung disease 22 (5), S15-S23, 2018 | 42 | 2018 |
| Evidence-based design of fixed-dose combinations: principles and application to pediatric anti-tuberculosis therapy EM Svensson, G Yngman, P Denti, H McIlleron, MC Kjellsson, ... Clinical Pharmacokinetics 57 (5), 591-599, 2018 | 42 | 2018 |
| Is there a role for tedizolid in the treatment of non-tuberculous mycobacterial disease? MM Ruth, VACM Koeken, LJ Pennings, EM Svensson, HFL Wertheim, ... Journal of Antimicrobial Chemotherapy 75 (3), 609-617, 2020 | 40 | 2020 |
Mats KarlssonUppsala UniversityПідтверджена електронна адреса в farmaci.uu.se
